Myovant Sciences Ltd

NYSE:MYOV   1:07:17 PM EDT
+0.11 (+0.63%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.59B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$21.8 Million
Adjusted EPS-$0.92
See more estimates
10-Day MA$18.12
50-Day MA$21.59
200-Day MA$20.11
See more pivots

Myovant Sciences Ltd Stock, NYSE:MYOV

11-12 St. Jamesâ??s Square, Suite 1, London, Greater London SW1Y 4LB
Phone: +44.20.7400.3351
Number of Employees: 214


Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.